Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RCEL · against 443 other Healthcare companies of similar size
Ranked #284 of 444 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score161 peers with a valuation score of 0–9, including RCEL · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | RCEL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 432 reported | -9.4% | 0.4% | 27% | 30% | |
| EBITDA yieldHigher is better · 449 reported | -6.4% | 3.1% | 24% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -5.3% | -7.5% | 53% | 20% | |
| Book yieldHigher is better · 442 reported | -5.9% | 48.9% | 4% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 284 | 302M USD | 8 | 42 | |
| 284 | 825M USD | 8 | 24 | |
| 284 | 427M USD | 8 | 7 | |
| 284 | 421M USD | 8 | 52 | |
| 284 | 474M USD | 8 | 25 | |
| 284 | 504M USD | 8 | 24 | |
| 284 | 388M USD | 8 | 36 | |
| 284 | 730M USD | 8 | 11 | |
| 284 | 468M USD | 8 | 40 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score